The Trucheck™ Intelli can detect over 70 types of cancer. Including the most common cancers; breast, bowel, prostate, ovarian, and lung cancers (see full list below).

Trucheck™ cannot detect blood or lymphatic system cancers because CTCs are associated with solid organ malignancies.

Trucheck™ Intelli has been validated for the detection of the following types of cancer:

• Adenocarcinoma ( Salivary Duct, Thyroid, Breast, lung, Oesophagus, Stomach, Duodenum,
  Jejunum, Ileum, Colon, Rectum, Pancreas, Gallbladder, Bile Duct, Liver, Ovary, Prostate, Uterus);
• Squamous Cell Carcinoma (SCC; Buccal Mucosa, Hard Palate, Larynx, Lip, Oral Cavity, Paranasal Sinus, Pharynx, Pyriform Fossa, Retromolar Trigone, Soft palate, Tongue, Tonsil, Oesophagus, Lung, Penis, Cervix, Vulva, Vagina, Anorectal, Skin);
• Adenosquamous Carcinoma (Oesophagus, Lung);
• Neuroendocrine (Lung, Esophagus, Duodenum, Jejunum, lleum, Thymus, Adrenal, Pancreas, Prostate, Colon, Rectum);
• Renal Cell Carcinoma (Kidney);
• Transitional Cell Carcinoma (Bladder, Renal Pelvis, Ureter);
• Gastrointestinal Stromal tumors (Stomach, Duodenum, lleum, Jejunum, Colon, Rectum);
• Melanomas (Cutaneous, Mucosal);
• Mesothelioma (Plural, Peritoneal);
• Sarcomas (Carcinosarcoma, Chondrosarcoma, Leiomyosarcoma, Osteosarcoma, Liposarcoma);
• Small Cell Lung Cancer (Lung);
• Glioma.

Trucheck™ Femmesafe test screens for a limited number of cancers in women.

• Adenocarcinoma of Breast
• Adenocarcinoma of the Ovary
• Adenocarcinoma of the Uterus
• Squamous cell carcinoma of Cervix.

Age is a significant risk factor for nearly all cancers. We want to target these cancer screening tests at people likely to benefit from testing.

Trucheck™ Intelli: Adults over 40 years of age

Trucheck Femmesafe: Females over 40 years of age

Individuals aged 35 to 39 years of age, only if ONE of the risk factors below apply

• • A family history of cancer and/or known carrier status
  • Presence of risk associated Hereditary germline mutation/s
  • Obesity (BMI over 30)
  • Type 2 diabetes
  • History of Infectious Diseases (HPV, hepatitis B or hepatitis C viruses)
  • Documented/ significant exposure to specific chemicals and carcinogens

The laboratory will usually share your results with your doctor within 2 weeks. At your test consultation, you can decide with your doctor how you would like to receive your results. We offer all patients a free face to face follow-up consultation. If you prefer you may decide with your doctor to receive your results by telephone. 

A positive result means CTCs indicative of Trucheck™ positivity have been detected in your sample, which is suggestive of a higher chance of detection of malignancy (cancer). The sample result will also usually suggest the likely organ of origin and cancer type.

Your doctor will discuss with you suitable next steps to confirm if cancer is present. This will usually mean considering further diagnostic tests such as scans and biopsies.

A negative result means CTCs were not detected in your sample. The chance of having an active malignancy present in the body is low.
A negative Trucheck report does not completely rule out the possibility of cancer as some cancers may not she detectable tumour cells in the blood.

You can enjoy the peace of mind given by the negative test result.

No. The test is designed for people without symptoms. If you have symptoms, you should seek urgent medical advice.

In the future, the tests may be used to help guide which patients with symptoms need further checks such as a biopsy but this is still at a research stage.

In studies, the test is positive in both early and late-stage cancers. This is good because many current tests only detect cancers when they are at an advanced or late stage. Early diagnosis is likely to make treatment more successful.

No. It is only suitable for people who have not had cancer.

There are other similar tests available to monitor patients after cancer treatment. We would recommend you speak with your treating doctor or surgeon to see if there is a test suitable for you.

It can be a useful addition to your yearly health screening or medical check-up. You should discuss this with your Doctor how often or when is the right time for you to test.

No. Trucheck™ tests are designed to be used in addition to, and not replace, conventional cancer screening. This includes standard tests such as mammograms, cervical screening and bowel cancer screening. 

Trucheck™ can detect cancers at an early stage before symptoms appear.

• Trucheck™ Intelli is a blood test that can detect more than 70 types of early-stage cancer within the asymptomatic population.
  • Trucheck Intelli has an overall sensitivity of 88.2% – meaning that for every 100 patients tested who have cancer, it will correctly identify 88 of those patients, resulting in a 12% false negative rate.
• Trucheck™ Femmesafe is a blood test that can detect adenocarcinoma (cancer) of the breast, uterus, ovary and squamous cell carcinoma of the cervix in asymptomatic women.
  • Trucheck Breast has a sensitivity of 88.2% – meaning that for every 100 patients tested who have cancer, it will correctly identify 88 of those patients, resulting in a 12% false negative rate.

All Trucheck tests have a specificity of 96% – meaning that for every 100 people tested, that do not have cancer, Trucheck will correctly identify 96 of these individuals, resulting in a 4% false positive rate.

False positives occur in all screening tests, the 4% level in Trucheck tests compares very favourably with other cancer screening such as PSA testing (75%), FIT testing (25%) and mammograms (7-12% at first mammogram).

Yes, we believe the Cancer Screening blood test is a really powerful addition to our health screening. It is not designed to replace standard health screening tests so should be done alongside your routine healthcare. Check out our packages here.

If you have more questions about the test itself then the laboratory has lots of detailed scientific information available here.

The total fees include your pre and post-test consultations with the doctor at our clinic, sample taking and all laboratory and report fees.

Trucheck™ Intelli – up to 70 solid tumours – £1250

Trucheck™ Femmesafe – £950

In the event of positive results showing a high risk of cancer it is likely that further checks such as scans or biopsies are likely to be recommended. These tests may not be covered by private medical insurance or provided by the NHS, especially prior to a cancer diagnosis.